Zhejiang Orient Gene Biotech was founded in December 2005 and listed on the SEE STAR Market on February 5, 2020 (securities code: 688298). Orient Gene specializes in R&D, production, and sales of in vitro diagnostic products. Their product range includes infectious diseases (including COVID-19 test series), toxicology, tumor markers, cardiac markers, and fertility testing. With a wide range of detection products and supporting biomaterials, the company has a complete industrial chain, covering upstream core antigen/antibody biomaterials to POCT rapid diagnostic reagents and instruments.
Diagnostics | Electromedical Equipment / Medical Technology
